K. Hostettler (Basel, Switzerland)
to present important clinical trials in respiratory medicine; to summarise key findings and discuss with the audience experts conclusions, to bring clinical trial’s abstracts into the clinical context. This session is led by a chair and two expert discussants who will facilitate the discussions and summarise key messages.
Late Breaking Abstract - Exploring Efficacy and Safety of oral Pirfenidone for progressive, non-IPF Lung Fibrosis (RELIEF)
A. Guenther (Giessen, Germany), A. Prasse (Hannover, Germany), M. Kreuter (Heidelberg, Germany), P. Neuser (Marburg, Germany), K. Rabe (Grossharnsdorf, Germany), F. Bonella (Essen, Germany), R. Bonnet (Bad Berka, Germany), C. Grohe (Berlin, Germany), M. Held (Würzburg, Germany), H. Wilkens (Homburg, Germany), P. Hammerl (Immenhausen, Germany), D. Koschel (Dresden, Germany), S. Blaas (Regensburg, Germany), H. Wirtz (Leipzig, Germany), J. Ficker (Nürnberg, Germany), W. Neumeister (Koblenz, Germany), N. Schönfeld (Berlin, Germany), M. Claussen (Grossharnsdorf, Germany), N. Kneidinger (Munich, Germany), M. Frankenberger (Munich, Germany), S. Hummler (Heidelberg, Germany), N. Kahn (Heidelberg, Germany), S. Tello (Giessen, Germany), J. Freise (Hannover, Germany), T. Welte (Hannover, Germany), C. Schade-Brittinger (Marburg, Germany), J. Behr (Münich, Germany)
|    |
Late Breaking Abstract - Phase II trial of pirfenidone in patients with progressive fibrosing unclassifiable ILD (uILD)
T. Maher (London, United Kingdom), T. Corte (Camperdown, Australia), A. Fischer (Denver, United States of America), M. Kreuter (Heidelberg, Germany), D. Lederer (New York, United States of America), M. Molina-Molina (Barcelona, Spain), J. Axmann (Basel, Switzerland), K. Kirchgaessler (Basel, Switzerland), K. Samara (Maroussi, Greece), F. Gilberg (Basel, Switzerland), V. Cottin (Lyon, France)
|  |
Nintedanib in patients with chronic fibrosing interstitial lung diseases with progressive phenotype: the INBUILD trial
K. Flaherty (Ann Arbor, MI, United States of America), A. Wells (London, United Kingdom), V. Cottin (Lyon, France), A. Devaraj (London, United Kingdom), Y. Inoue (Osaka, Japan), L. Richeldi (Rome, Italy), S. Walsh (London, United Kingdom), S. Stowasser (Ingelheim am Rhein, Germany), C. Coeck (Brussels, Belgium), R. Goeldner (Biberach, Germany), E. Clerisme-Beaty (Ingelheim am Rhein, Germany), R. Schlenker-Herceg (Ridgefield, CT, United States of America), K. Brown (Denver, CO, United States of America)
| |
Changes in FVC in the SENSCIS trial of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD)
K. Highland (Cleveland, Ohio, United States of America), A. Azuma (Tokyo, Japan), A. Fischer (Denver, Colorado, United States of America), M. Kuwana (Tokyo, Japan), T. Maher (London , United Kingdom), M. Mayes (Houston, Texas, United States of America), G. Raghu (Seattle, United States of America), M. Girard (Reims, France), M. Alves (Ingelheim am Rhein, Germany), M. Gahlemann (Basel , Switzerland), O. Distler (Zurich, Switzerland)
| |
Lung function preservation in a phase 3 trial of tocilizumab (TCZ) in systemic sclerosis (SSc)
C. Denton (London, United Kingdom), C. Lin (South San Francisco, United States of America), J. Goldin (Los Angeles, United States of America), G. Kim (Los Angeles, United States of America), M. Kuwana (Tokyo, Japan), Y. Allanore (Paris, France), A. Batalov (Plovdiv, Bulgaria), I. Butrimiene (Vilnius, Lithuania), P. Carreira (Madrid, Spain), M. Matucci-Cerinic (Florence, Italy), O. Distler (Zurich, Switzerland), D. Martinovic Kaliterna (Split, Croatia), C. Mihai (Bucharest, Romania), M. Mogensen (Copenhagen, Denmark), M. Olesinska (Warsaw, Poland), J. Pope (London, Canada), G. Riemekasten (Berlin, Germany), T. Rodriguez-Reyne (Mexico City, Mexico), M. Santos (Almada, Portugal), J. Van Laar (Utrecht, Netherlands), H. Spotswood (Welwyn Garden City, United Kingdom), J. Siegel (South San Francisco, United States of America), A. Jahreis (South San Francisco, United States of America), D. Furst (Los Angeles, United States of America), D. Khanna (Ann Arbor, United States of America)
| |
Late Breaking Abstract - Safety and efficacy of B-cell depletion with rituximab for the treatment of systemic sclerosis-associated pulmonary arterial hypertension.
R. Zamanian (Stanford, United States of America), D. Badesch (Denver, United States of America), L. Chung (Stanford, United States of America), R. Domsic (Pittsburg, United States of America), T. Medsger (Pittsburg, United States of America), A. Pinckney (Durham, United States of America), L. Keyes-Elstein (Durham, United States of America), C. D'Aveta (Durham, United States of America), M. Spychala (Durham, United States of America), J. White (Rochester, United States of America), P. Hassoun (Baltimore, United States of America), F. Torres (Dallas, United States of America), J. Molitor (Minneapolis, United States of America), D. Khanna (AnnArbor, United States of America), H. Maeker (Stanford, United States of America), B. Welch (Bethesda, United States of America), E. Goldmuntz (Bethesda, United States of America), M. Nicolls (Stanford, United States of America), . On Behalf Of Asco1 Investigators (- , United States of America)
| |
Late Breaking Abstract - Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension: results from the randomised controlled RACE study
X. Jais (Le Kremlin-Bicêtre, France), P. Brenot (Le Plessis robinson, France), H. Bouvaist (Grenoble, France), M. Canuet (Strasbourg, France), C. Chabanne (Rennes, France), A. Chaouat (Nancy, France), V. Cottin (Bron, France), P. De Groote (Lille, France), C. Dromer (Bordeaux, France), N. Favrolt (Dijon, France), C. Garcia Alonso (Le Plessis Robinson, France), B. Gérardin (Le Plessis Robinson, France), D. Horeau-Langlard (Nantes, France), M. Jevnikar (Le Kremlin-Bicêtre, France), P. Magro (Tours, France), D. Montani (Le Kremlin-Bicêtre, France), F. Parent (Le Kremlin-Bicêtre, France), C. Pison (Grenoble, France), G. Prévot (Toulouse, France), S. Renard (Marseille, France), L. Savale (Le Kremlin-Bicêtre, France), A. Simon (Poitiers, France), O. Sitbon (Le Kremlin-Bicêtre, France), R. Tresorier (Clermont-Ferrand, France), C. Tromeur (Brest, France), H. Agostini (Le Kremlin-Bicêtre, France), C. Piedvache (Le Kremlin-Bicêtre, France), E. Fadel (Le Plessis Robinson, France), M. Humbert (Le Kremlin-Bicêtre, France), G. Simonneau (Le Kremlin-Bicêtre, France)
| |
Late Breaking Abstract - Transbronchial lung cryobiopsy for interstitial lung disease diagnosis: results of the COLDICE Study
L. Troy (Sydney, Australia), C. Grainge (Newcastle, Australia), T. Corte (Sydney, Australia), J. Williamson (Sydney, Australia), M. Vallely (Sydney, Australia), W. Cooper (Sydney, Australia), A. Mahar (Sydney, Australia), J. Myers (Michigan, United States of America), S. Lai (Sydney, Australia), E. Mulyadi (Sydney, Australia), P. Torzillo (Sydney, Australia), M. Phillips (Perth, Australia), H. Jo (Sydney, Australia), S. Webster (Sydney, Australia), Q. Lin (Sydney, Australia), J. Rhodes (Sydney, Australia), M. Salamonsen (Perth, Australia), J. Wrobel (Perth, Australia), B. Harris (Sydney, Australia), G. Don (Sydney, Australia), P. Wu (Sydney, Australia), B. Ng (Sydney, Australia), C. Oldmeadow (Newcastle, Australia), G. Raghu (Seattle, United States of America), E. Lau (Sydney, Australia), .. Coldice Investigators (Sydney, Australia)
| |